Last 12 months
Inside the activity.
0 purchase rows · 16 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 7 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 5 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 2 |
| Jul 2026 | 0 | 1 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 1 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 29, 2019 Filed Jul 31, 2019 21:59 UTC |
Lerman Bradley ESVP General Counsel & Corp Sec
|
GrantOrdinary Shares | 10,330 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-025556 · form4.xml · nonDerivative · entry 1 Lerman Bradley E · CIK 0001559405 · SVP General Counsel & Corp Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,038 F1 · kind: The restrictions on these restricted stock units shall lapse 100% on the third anniversary of the Grant Date if the Company's cumulative non-GAAP diluted earnings per share ("EPS") growth during the 36-month period ending on the last day of the Company's fiscal year 2022 equals or exceeds a 3% cumulative compound annual growth rate, as determined by the Compensation Committee. F2 · balance_after: This balance increased by 1,055 shares due to exempt transactions such as dividend reinvestment and employee stock purchase plan. Read SEC document |
| July 29, 2019 Filed Jul 31, 2019 22:04 UTC |
Martha GeoffreyEVP & GroupPres Restora Therap
|
GrantStock Option (Right to Buy) · Derivative | 1,615 | $0.00 Strike: $103.26 | $0.00 |
DisclosureSEC source: 0001127602-19-025558 · form4.xml · derivative · entry 3 Martha Geoffrey · CIK 0001560409 · EVP & GroupPres Restora Therap 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,615 Underlying: Ordinary Shares · 1,615 shares Expires 2029-07-29 F3 · derivative.exercise_date: These options become exercisable at the rate of 25% of the shares granted per year beginning on the first anniversary of grant. Read SEC document |
| July 29, 2019 Filed Jul 31, 2019 22:04 UTC |
Martha GeoffreyEVP & GroupPres Restora Therap
|
GrantStock Option (Right to Buy) · Derivative | 81,820 | $0.00 Strike: $103.26 | $0.00 |
DisclosureSEC source: 0001127602-19-025558 · form4.xml · derivative · entry 2 Martha Geoffrey · CIK 0001560409 · EVP & GroupPres Restora Therap 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,820 Underlying: Ordinary Shares · 81,820 shares Expires 2029-07-29 F3 · derivative.exercise_date: These options become exercisable at the rate of 25% of the shares granted per year beginning on the first anniversary of grant. Read SEC document |
| July 29, 2019 Filed Jul 31, 2019 22:04 UTC |
Martha GeoffreyEVP & GroupPres Restora Therap
|
GrantOrdinary Shares | 12,267 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-025558 · form4.xml · nonDerivative · entry 1 Martha Geoffrey · CIK 0001560409 · EVP & GroupPres Restora Therap 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,412 F1 · kind: The restrictions on these restricted stock units shall lapse 100% on the third anniversary of the Grant Date if the Company's cumulative non-GAAP diluted earnings per share ("EPS") growth during the 36-month period ending on the last day of the Company's fiscal year 2022 equals or exceeds a 3% cumulative compound annual growth rate, as determined by the Compensation Committee. F2 · balance_after: This balance increased by 227 shares due to exempt transactions such as dividend reinvestment. Read SEC document |
| July 29, 2019 Filed Jul 31, 2019 18:13 UTC |
TEN HOEDT ROBEVP & President EMEA
|
GrantStock Option (Right to Buy) · Derivative | 1,615 | $0.00 Strike: $103.26 | $0.00 |
DisclosureSEC source: 0001127602-19-025565 · form4.xml · derivative · entry 3 TEN HOEDT ROB · CIK 0001610036 · EVP & President EMEA 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,615 Underlying: Ordinary Shares · 1,615 shares Expires 2029-07-29 F3 · derivative.exercise_date: These options become exercisable at the rate of 25% of the shares granted per year beginning on the first anniversary of grant. Read SEC document |
| July 29, 2019 Filed Jul 31, 2019 18:13 UTC |
TEN HOEDT ROBEVP & President EMEA
|
GrantStock Option (Right to Buy) · Derivative | 60,288 | $0.00 Strike: $103.26 | $0.00 |
DisclosureSEC source: 0001127602-19-025565 · form4.xml · derivative · entry 2 TEN HOEDT ROB · CIK 0001610036 · EVP & President EMEA 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,288 Underlying: Ordinary Shares · 60,288 shares Expires 2029-07-29 F3 · derivative.exercise_date: These options become exercisable at the rate of 25% of the shares granted per year beginning on the first anniversary of grant. Read SEC document |
| July 29, 2019 Filed Jul 31, 2019 18:13 UTC |
TEN HOEDT ROBEVP & President EMEA
|
GrantOrdinary Shares | 9,039 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-025565 · form4.xml · nonDerivative · entry 1 TEN HOEDT ROB · CIK 0001610036 · EVP & President EMEA 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,039 F1 · kind: The restrictions on these restricted stock units shall lapse 100% on the third anniversary of the Grant Date if the Company's cumulative non-GAAP diluted earnings per share ("EPS") growth during the 36-month period ending on the last day of the Company's fiscal year 2022 equals or exceeds a 3% cumulative compound annual growth rate, as determined by the Compensation Committee. F2 · balance_after: This balance increased by 215 shares due to exempt transactions such as dividend reinvestment. Read SEC document |
| July 29, 2019 Filed Jul 31, 2019 17:50 UTC |
HAKAMI HOOMANEVP & Group President Diabetes
|
GrantStock Option (Right to Buy) · Derivative | 1,615 | $0.00 Strike: $103.26 | $0.00 |
DisclosureSEC source: 0001127602-19-025553 · form4.xml · derivative · entry 3 HAKAMI HOOMAN · CIK 0001610035 · EVP & Group President Diabetes 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,615 Underlying: Ordinary Shares · 1,615 shares Expires 2029-07-29 F3 · derivative.exercise_date: These options become exercisable at the rate of 25% of the shares granted per year beginning on the first anniversary of grant. Read SEC document |
| July 29, 2019 Filed Jul 31, 2019 17:50 UTC |
HAKAMI HOOMANEVP & Group President Diabetes
|
GrantStock Option (Right to Buy) · Derivative | 53,829 | $0.00 Strike: $103.26 | $0.00 |
DisclosureSEC source: 0001127602-19-025553 · form4.xml · derivative · entry 2 HAKAMI HOOMAN · CIK 0001610035 · EVP & Group President Diabetes 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,829 Underlying: Ordinary Shares · 53,829 shares Expires 2029-07-29 F3 · derivative.exercise_date: These options become exercisable at the rate of 25% of the shares granted per year beginning on the first anniversary of grant. Read SEC document |
| July 29, 2019 Filed Jul 31, 2019 17:50 UTC |
HAKAMI HOOMANEVP & Group President Diabetes
|
GrantOrdinary Shares | 8,071 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-025553 · form4.xml · nonDerivative · entry 1 HAKAMI HOOMAN · CIK 0001610035 · EVP & Group President Diabetes 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,026 F1 · kind: The restrictions on these restricted stock units shall lapse 100% on the third anniversary of the Grant Date if the Company's cumulative non-GAAP diluted earnings per share ("EPS") growth during the 36-month period ending on the last day of the Company's fiscal year 2022 equals or exceeds a 3% cumulative compound annual growth rate, as determined by the Compensation Committee. F2 · balance_after: This balance increased by 282 shares due to exempt transactions such as dividend reinvestment and employee stock purchase plan. Read SEC document |
| July 22, 2019 Filed Jul 23, 2019 22:03 UTC |
Kuntz RichardSVP & Chief Medical & Science
|
SaleOrdinary Shares | 3,438 | $101.12 | $347,650.56 |
DisclosureSEC source: 0001127602-19-025080 · form4.xml · nonDerivative · entry 1 Kuntz Richard · CIK 0001341125 · SVP & Chief Medical & Science 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,127 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · balance_after: This balance increased by 324 shares due to exempt transactions such as dividend reinvestment. Read SEC document |
| June 21, 2019 Filed Jun 27, 2019 21:28 UTC |
PARKHILL KAREN LEVP & Chief Financial Officer
|
GiftOrdinary Shares | 300 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-022967 · form4.xml · nonDerivative · entry 4 PARKHILL KAREN L · CIK 0001527660 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Child #3 Disclosed balance after: 300 Read SEC document |
| June 21, 2019 Filed Jun 27, 2019 21:28 UTC |
PARKHILL KAREN LEVP & Chief Financial Officer
|
GiftOrdinary Shares | 300 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-022967 · form4.xml · nonDerivative · entry 3 PARKHILL KAREN L · CIK 0001527660 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Child #2 Disclosed balance after: 300 Read SEC document |
| June 21, 2019 Filed Jun 27, 2019 21:28 UTC |
PARKHILL KAREN LEVP & Chief Financial Officer
|
GiftOrdinary Shares | 300 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-022967 · form4.xml · nonDerivative · entry 2 PARKHILL KAREN L · CIK 0001527660 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Child #1 Disclosed balance after: 300 Read SEC document |
| June 21, 2019 Filed Jun 27, 2019 21:28 UTC |
PARKHILL KAREN LEVP & Chief Financial Officer
|
GiftOrdinary Shares | 900 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-022967 · form4.xml · nonDerivative · entry 1 PARKHILL KAREN L · CIK 0001527660 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,507 Read SEC document |
| June 20, 2019 Filed Jun 21, 2019 21:43 UTC |
PARKHILL KAREN LEVP & Chief Financial Officer
|
Tax withholdingOrdinary Shares | 6,945 | $99.26 | $689,360.70 |
DisclosureSEC source: 0001127602-19-022538 · form4.xml · nonDerivative · entry 1 PARKHILL KAREN L · CIK 0001527660 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,407 F1 · balance_after: This balance increased by 672 shares due to exempt transactions such as dividend reinvestment. Read SEC document |
| June 17, 2019 Filed Jun 18, 2019 17:31 UTC |
Surface Carol ASVP, Chief HR Officer
|
SaleOrdinary Shares | 9,000 | $97.66 | $878,976.00 |
DisclosureSEC source: 0001127602-19-022044 · form4.xml · nonDerivative · entry 1 Surface Carol A · CIK 0001485966 · SVP, Chief HR Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,158 F1 · balance_after: This balance increased by 659 shares due to exempt transactions such as dividend reinvestment. Read SEC document |
| June 12, 2019 Filed Jun 14, 2019 16:51 UTC |
HAKAMI HOOMANEVP & Group President Diabetes
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 31,731 | $0.00 Strike: $78.00 | $0.00 |
DisclosureSEC source: 0001127602-19-021658 · form4.xml · derivative · entry 4 HAKAMI HOOMAN · CIK 0001610035 · EVP & Group President Diabetes 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,578 Underlying: Ordinary Shares · 31,731 shares Expires 2025-08-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F5 · derivative.exercise_date: These options to purchase ordinary shares of New Medtronic for $62.76 per share, which were unvested at the effective time of the Merger, were received in the Merger and represent the conversion of an equal number of Medtronic common stock shares for $62.76 per share. The New Medtronic stock option has the same terms and conditions as the original Medtronic stock option. These options became exercisable in four equal annual installments beginning on July 28, 2015, which was the first anniversary of the grant. Read SEC document |
| June 12, 2019 Filed Jun 14, 2019 16:51 UTC |
HAKAMI HOOMANEVP & Group President Diabetes
|
SaleOrdinary Shares | 20,933 | $97.49 | $2,040,758.17 |
DisclosureSEC source: 0001127602-19-021658 · form4.xml · nonDerivative · entry 3 HAKAMI HOOMAN · CIK 0001610035 · EVP & Group President Diabetes 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,673 F1 · kind: The exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $97.23 to $97.95, inclusive. The reporting person undertakes to provide to Medtronic plc, any security holder of Medtronic plc, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. F4 · balance_after: This balance increased by 959 shares due to exempt transactions such as dividend reinvestment and Employee Stock Purchase Plan. Read SEC document |
| June 12, 2019 Filed Jun 14, 2019 16:51 UTC |
HAKAMI HOOMANEVP & Group President Diabetes
|
SaleOrdinary Shares | 31,731 | $97.49 | $3,093,455.19 |
DisclosureSEC source: 0001127602-19-021658 · form4.xml · nonDerivative · entry 2 HAKAMI HOOMAN · CIK 0001610035 · EVP & Group President Diabetes 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,606 F1 · kind: The exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $97.22 to $97.96, inclusive. The reporting person undertakes to provide to Medtronic plc, any security holder of Medtronic plc, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| June 12, 2019 Filed Jun 14, 2019 16:51 UTC |
HAKAMI HOOMANEVP & Group President Diabetes
|
Exercise / conversionOrdinary Shares | 31,731 | $78.00 | $2,475,018.00 |
DisclosureSEC source: 0001127602-19-021658 · form4.xml · nonDerivative · entry 1 HAKAMI HOOMAN · CIK 0001610035 · EVP & Group President Diabetes 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,337 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| June 06, 2019 Filed Jun 7, 2019 21:34 UTC |
Martha GeoffreyEVP & GroupPres Restora Therap
|
SaleOrdinary Shares | 11,000 | $96.05 | $1,056,583.00 |
DisclosureSEC source: 0001127602-19-021136 · form4.xml · nonDerivative · entry 1 Martha Geoffrey · CIK 0001560409 · EVP & GroupPres Restora Therap 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,918 F1 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $95.75 to $96.45, inclusive. The reporting person undertakes to provide to Medtronic plc, any security holder of Medtronic plc, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. F2 · balance_after: This balance increased by 716 shares due to exempt transactions such as dividend reinvestment. Read SEC document |
| May 28, 2019 Filed May 29, 2019 17:37 UTC |
TEN HOEDT ROBEVP & President EMEA
|
SaleOrdinary Shares | 9,000 | $91.88 | $826,920.00 |
DisclosureSEC source: 0001127602-19-020188 · form4.xml · nonDerivative · entry 1 TEN HOEDT ROB · CIK 0001610036 · EVP & President EMEA 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,785 F1 · security: This balance increased by 677 shares due to exempt transactions such as dividend reinvestment. Read SEC document |
| May 28, 2019 Filed Jun 12, 2019 18:18 UTC Amendment |
TEN HOEDT ROBEVP & President EMEA
|
SaleOrdinary Shares | 9,000 | $91.88 | $826,920.00 |
DisclosureSEC source: 0001127602-19-021497 · form4a.xml · nonDerivative · entry 1 TEN HOEDT ROB · CIK 0001610036 · EVP & President EMEA 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,785 F1 · security: This balance increased by 677 shares due to exempt transactions such as dividend reinvestment. Read SEC document |
| May 24, 2019 Filed May 28, 2019 23:54 UTC |
ANDERSON RICHARD HDirector
|
PurchaseOrdinary Shares | 10,900 | $92.40 | $1,007,160.00 |
DisclosureSEC source: 0001127602-19-020054 · form4.xml · nonDerivative · entry 1 ANDERSON RICHARD H · CIK 0001200334 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,912 Read SEC document |
| April 30, 2019 Filed May 1, 2019 16:25 UTC |
OLEARY DENISE MDirector
|
Tax withholdingOrdinary Shares | 429 | $88.81 | $38,099.49 |
DisclosureSEC source: 0000914190-19-000134 · edgar.xml · nonDerivative · entry 2 OLEARY DENISE M · CIK 0001145159 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,236 Read SEC document |
| April 30, 2019 Filed May 1, 2019 20:28 UTC |
Powell Kendall JDirector
|
Tax withholdingOrdinary Shares | 537 | $88.81 | $47,690.97 |
DisclosureSEC source: 0001127602-19-016734 · form4.xml · nonDerivative · entry 2 Powell Kendall J · CIK 0001298823 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,247 Read SEC document |
| April 30, 2019 Filed May 1, 2019 20:16 UTC |
DONNELLY SCOTT CDirector
|
Tax withholdingOrdinary Shares | 429 | $88.81 | $38,099.49 |
DisclosureSEC source: 0001127602-19-016717 · form4.xml · nonDerivative · entry 2 DONNELLY SCOTT C · CIK 0001233158 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,930 Read SEC document |
| April 30, 2019 Filed May 1, 2019 20:15 UTC |
ARNOLD CRAIGDirector
|
Tax withholdingOrdinary Shares | 429 | $88.81 | $38,099.49 |
DisclosureSEC source: 0001127602-19-016713 · form4.xml · nonDerivative · entry 2 ARNOLD CRAIG · CIK 0001188578 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,624 Read SEC document |
| April 30, 2019 Filed May 1, 2019 16:24 UTC |
Lenehan James TDirector
|
Tax withholdingOrdinary Shares | 429 | $88.81 | $38,099.49 |
DisclosureSEC source: 0001127602-19-016732 · form4.xml · nonDerivative · entry 2 Lenehan James T · CIK 0001189009 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,522 Read SEC document |
| April 30, 2019 Filed May 1, 2019 20:20 UTC |
HOGAN RANDALL JDirector
|
Tax withholdingOrdinary Shares | 429 | $88.81 | $38,099.49 |
DisclosureSEC source: 0001127602-19-016724 · form4.xml · nonDerivative · entry 2 HOGAN RANDALL J · CIK 0001189049 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,150 Read SEC document |
| April 30, 2019 Filed May 1, 2019 20:13 UTC |
ANDERSON RICHARD HDirector
|
Tax withholdingOrdinary Shares | 429 | $88.81 | $38,099.49 |
DisclosureSEC source: 0001127602-19-016712 · form4.xml · nonDerivative · entry 2 ANDERSON RICHARD H · CIK 0001200334 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,012 Read SEC document |
| April 30, 2019 Filed May 1, 2019 20:26 UTC |
NABEL ELIZABETH GDirector
|
Tax withholdingOrdinary Shares | 429 | $88.81 | $38,099.49 |
DisclosureSEC source: 0001127602-19-016733 · form4.xml · nonDerivative · entry 2 NABEL ELIZABETH G · CIK 0001619929 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,023 Read SEC document |
| April 30, 2019 Filed Jun 12, 2019 22:17 UTC Amendment |
Powell Kendall JDirector
|
Tax withholdingOrdinary Shares | 537 | $88.81 | $47,690.97 |
DisclosureSEC source: 0001127602-19-021496 · form4a.xml · nonDerivative · entry 2 Powell Kendall J · CIK 0001298823 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,247 Read SEC document |
| April 30, 2019 Filed Jun 12, 2019 18:13 UTC Amendment |
Lenehan James TDirector
|
Tax withholdingOrdinary Shares | 429 | $88.81 | $38,099.49 |
DisclosureSEC source: 0001127602-19-021493 · form4a.xml · nonDerivative · entry 2 Lenehan James T · CIK 0001189009 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,522 Read SEC document |
| April 30, 2019 Filed Jun 12, 2019 22:01 UTC Amendment |
DONNELLY SCOTT CDirector
|
Tax withholdingOrdinary Shares | 429 | $88.81 | $38,099.49 |
DisclosureSEC source: 0001127602-19-021487 · form4a.xml · nonDerivative · entry 2 DONNELLY SCOTT C · CIK 0001233158 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,930 Read SEC document |
| April 30, 2019 Filed Jun 12, 2019 21:59 UTC Amendment |
ARNOLD CRAIGDirector
|
Tax withholdingOrdinary Shares | 429 | $88.81 | $38,099.49 |
DisclosureSEC source: 0001127602-19-021484 · form4a.xml · nonDerivative · entry 2 ARNOLD CRAIG · CIK 0001188578 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,624 Read SEC document |
| April 30, 2019 Filed Jun 12, 2019 22:04 UTC Amendment |
HOGAN RANDALL JDirector
|
Tax withholdingOrdinary Shares | 429 | $88.81 | $38,099.49 |
DisclosureSEC source: 0001127602-19-021489 · form4a.xml · nonDerivative · entry 2 HOGAN RANDALL J · CIK 0001189049 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,150 Read SEC document |
| April 30, 2019 Filed Jun 12, 2019 21:56 UTC Amendment |
ANDERSON RICHARD HDirector
|
Tax withholdingOrdinary Shares | 429 | $88.81 | $38,099.49 |
DisclosureSEC source: 0001127602-19-021481 · form4a.xml · nonDerivative · entry 2 ANDERSON RICHARD H · CIK 0001200334 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,012 Read SEC document |
| April 30, 2019 Filed Jun 12, 2019 22:15 UTC Amendment |
NABEL ELIZABETH GDirector
|
Tax withholdingOrdinary Shares | 429 | $88.81 | $38,099.49 |
DisclosureSEC source: 0001127602-19-021495 · form4a.xml · nonDerivative · entry 2 NABEL ELIZABETH G · CIK 0001619929 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,023 Read SEC document |
| April 29, 2019 Filed May 1, 2019 16:25 UTC |
OLEARY DENISE MDirector
|
GrantOrdinary Shares | 2,002 | $0.00 | $0.00 |
DisclosureSEC source: 0000914190-19-000134 · edgar.xml · nonDerivative · entry 1 OLEARY DENISE M · CIK 0001145159 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,665 F1 · kind: This restricted stock unit award will vest on the one year anniversary of the grant date. F2 · balance_after: This balance increased by 179 shares due to exempt transactions such as dividend reinvestment. Read SEC document |
| April 29, 2019 Filed May 1, 2019 20:28 UTC |
Powell Kendall JDirector
|
GrantOrdinary Shares | 2,002 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-016734 · form4.xml · nonDerivative · entry 1 Powell Kendall J · CIK 0001298823 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,784 F1 · kind: This restricted stock unit award will vest on the one year anniversary of the grant date. F2 · balance_after: This balance increased by 524 shares due to exempt transactions such as dividend reinvestment. Read SEC document |
| April 29, 2019 Filed May 1, 2019 20:16 UTC |
DONNELLY SCOTT CDirector
|
GrantOrdinary Shares | 2,002 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-016717 · form4.xml · nonDerivative · entry 1 DONNELLY SCOTT C · CIK 0001233158 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,359 F1 · kind: This restricted stock unit award will vest on the one year anniversary of the grant date. F2 · balance_after: This balance increased by 98 shares due to exempt transactions such as dividend reinvestment. Read SEC document |
| April 29, 2019 Filed May 1, 2019 20:15 UTC |
ARNOLD CRAIGDirector
|
GrantOrdinary Shares | 2,002 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-016713 · form4.xml · nonDerivative · entry 1 ARNOLD CRAIG · CIK 0001188578 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,053 F1 · kind: This restricted stock unit award will vest on the one year anniversary of the grant date. F2 · balance_after: This balance increased by 50 shares due to exempt transactions such as dividend reinvestment. Read SEC document |
| April 29, 2019 Filed May 1, 2019 16:24 UTC |
Lenehan James TDirector
|
GrantOrdinary Shares | 2,002 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-016732 · form4.xml · nonDerivative · entry 1 Lenehan James T · CIK 0001189009 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,951 F1 · kind: This restricted stock unit award will vest on the one year anniversary of the grant date. F2 · balance_after: This balance increased 141 shares due to exempt transactions such as dividend reinvestment. Read SEC document |
| April 29, 2019 Filed May 1, 2019 20:20 UTC |
HOGAN RANDALL JDirector
|
GrantOrdinary Shares | 2,002 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-016724 · form4.xml · nonDerivative · entry 1 HOGAN RANDALL J · CIK 0001189049 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,579 F1 · kind: This restricted stock unit award will vest on the one year anniversary of the grant date. F2 · balance_after: This balance increased by 50 shares due to exempt transactions such as dividend reinvestment. Read SEC document |
| April 29, 2019 Filed May 1, 2019 20:13 UTC |
ANDERSON RICHARD HDirector
|
GrantOrdinary Shares | 2,002 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-016712 · form4.xml · nonDerivative · entry 1 ANDERSON RICHARD H · CIK 0001200334 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,441 F1 · kind: This restricted stock unit award will vest on the one-year anniversary of the grant date. F2 · balance_after: This balance increased by 519 shares due to exempt transactions such as dividend reinvestment. Read SEC document |
| April 29, 2019 Filed May 1, 2019 20:22 UTC |
LEAVITT MICHAEL ODirector
|
GrantOrdinary Shares | 2,002 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-016729 · form4.xml · nonDerivative · entry 1 LEAVITT MICHAEL O · CIK 0001536118 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,311 F1 · kind: This restricted stock unit award will vest on the one year anniversary of the grant date. F2 · balance_after: This balance increased by 219 shares due to exempt transactions such as dividend reinvestment. Read SEC document |
| April 29, 2019 Filed May 1, 2019 20:26 UTC |
NABEL ELIZABETH GDirector
|
GrantOrdinary Shares | 2,002 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-016733 · form4.xml · nonDerivative · entry 1 NABEL ELIZABETH G · CIK 0001619929 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,452 F1 · kind: This restricted stock unit award will vest on the one year anniversary of the grant date. F2 · balance_after: This balance increased by 50 shares due to exempt transactions such as dividend reinvestment. Read SEC document |
| April 29, 2019 Filed May 1, 2019 20:17 UTC |
Goldsmith Andrea JoDirector
|
GrantOrdinary Shares | 259 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-016719 · form4.xml · nonDerivative · entry 1 Goldsmith Andrea Jo · CIK 0001730514 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 259 F1 · kind: This restricted stock unit award will vest on the one year anniversary of the grant date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.